Insulet PODD
Healthcare · Medical - Devices · Synthos Deep Dive · 2026-07-03
The Overview
Insulet makes the Omnipod — a small, tubeless, wearable insulin pump that people with diabetes stick on their skin; the newest version (Omnipod 5) automatically adjusts insulin by talking to a glucose sensor. It is sold through pharmacies like a prescription, which makes it easy to start. The business is growing fast: sales rose about 31% last year and roughly 34% in the most recent quarter, and it now earns a real profit.
Here's the twist: the stock has fallen by more than half from its high last year, even though sales kept growing. So you may be getting a strong, growing company at a much cheaper price than a year ago. Our verdict is Buy — Tactical: worth owning, but as a smaller "satellite" bet, and it's smart to buy a little at a time because the chart is still falling.
What the three scores mean in plain words:
- Downside Risk 5/10 (middle). The company doesn't owe much money and the stock already crashed, which lowers the risk — but it's still not cheap on this year's profits, and it bounces around more than the market.
- Growth Quality 8/10 (strong). Sales and profits are growing fast and steadily, and it's the leader in its niche.
- Exponential Potential 6/10 (above average). Most diabetics still don't use a pump, and Insulet is only an ~$11B company, so there's real room to grow — but the fastest burst of growth is likely behind it.
The one big worry: almost all of Insulet's money comes from a single product family (Omnipod). If a competitor's pump wins, a sensor partner pulls back, or new weight-loss drugs shrink the diabetic pump market, the whole company feels it at once.
Putting a number on it: our fair-value estimate is $195 against a current price of $145.13 — real upside if our numbers are right.
Our summary metrics
Low leverage (net-debt/EBITDA 0.8×) & a ~53% drawdown already cushion valuation — but 38× trailing, beta 1.13 and a single-product story keep risk mid-pack.
~18-21% forward revenue CAGR, ~25% adj-EPS growth guided, 71% gross margin, ROIC 16% — a durable category leader.
Omnipod 5 pharmacy + international ramp and a Type-2 / closed-loop TAM expansion, at only ~$11B cap — real room to run, but growth is gently decelerating.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Omnipod 5 pharmacy + international ramp and a Type-2 / closed-loop TAM expansion, at only ~$11B cap — real room to run, but growth is gently decelerating.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $221 (high $280 / low $190; 35 Buy · 12 Hold · 3 Sell) — context, not our anchor |
| Valuation | 38× trailing EPS · 25× FY26E · 20× FY27E · 11× FY30E · EV/S 4.1× · EV/EBITDA 20.6× |
| Technicals | Downtrend, basing — $164, −53% off 52-wk high, below the 200-DMA ($248), RSI 64, −45% 12-mo (SPY +21%) |
| Conviction | Moderate — no expert voices in KB (breadth 0, 0 claims). The call rests on fundamentals + the quant screen, and is labeled as such |
| Position sizing | Satellite growth, ~2–3%, scale-in given the broken chart |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for PODD — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $145.13, 6% below the 50-day average ($154), 32% below the 200-day average ($215) — a downtrend. 59% below the 52-week high of $353, 9% above the 52-week low of $133.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $145.13 is currently inside the band (band $130–$163).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 45.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.14, positive momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = PODD · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Insulet Corporation (NASDAQ: PODD) is a ~$11B medical-device company headquartered in Acton, Massachusetts, focused on insulin delivery for people with insulin-dependent diabetes. Its entire franchise is the Omnipod platform — a small, tubeless, disposable "pod" that adheres to the skin and delivers up to three days of insulin without tubing or needles the user handles. The flagship Omnipod 5 is an automated insulin delivery (AID) system: the pod runs a proprietary control algorithm and integrates wirelessly with third-party continuous glucose monitors (Dexcom, Abbott FreeStyle Libre) to dose automatically. A tiny legacy Drug Delivery business supplies pods to Amgen (Neulasta Onpro). Fiscal year ends December 31. CEO Ashley McEvoy; ~5,400 employees.
The strategic edge is the pharmacy channel — Omnipod is dispensed as a pharmacy benefit rather than durable medical equipment, lowering the barrier to start versus tubed pumps. The forward growth legs are (a) international Omnipod 5 rollout, (b) U.S. pharmacy penetration of multiple-daily-injection (MDI) switchers, and (c) a Type-2-diabetes / fully-closed-loop expansion (EVOLVE pivotal study underway, 510(k) filing targeted 2027).
Revenue mix (FY2025, from FMP segmentation):
- By product line: Omnipod $2,674.1M (98.7%) · Drug Delivery $34.1M (1.3%). This is, for practical purposes, a one-product company — the single most important framing in this note.
- By geography: United States $1,953.9M (72%) · Non-US $754.3M (28%). International is the faster grower — Q1'26 International Omnipod was +59% reported / +45% constant-currency, versus +28% in the U.S.
2. The expert thesis
There is no expert coverage for PODD in the Synthos knowledge base. The claims file reports total_claims: 0, net_bullish_voices: 0, and an empty top array. No independent voice in our panel has spoken to this name.
Accordingly, this deep dive is fundamentals- and quant-driven, not conviction-driven, and I cite no claim_id values — because none exist, and Synthos never fabricates conviction. Where a conviction name (see the LLY note) leans on a broad panel of reconciled expert claims, PODD's verdict rests entirely on: the reported financials (FMP), the live analyst-estimate consensus, management's own dated guidance (SEC 8-K, half-weighted, §9), and the quant screen that surfaced it. Read the scores in §3 as the honest output of that narrower evidence base, and size the position accordingly.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Net-debt/EBITDA 0.81×, current ratio 2.5×, interest coverage 7.3× — a clean balance sheet; and the stock has already fallen ~53%, resetting valuation. But 38× trailing EPS, beta 1.13, and ~99% single-product concentration keep it mid-pack, not low. |
| Growth Quality | 8 · High | FY25 revenue +30.7%, ~18-21% forward revenue CAGR, ~25% guided adj-EPS growth, gross margin 71%, ROIC 16.4%, ROE 21.4% — a durable, self-funding category leader with expanding operating margin. |
| Exponential Potential | 6 · Moderate-High | Large under-penetrated pump TAM (most insulin-dependent diabetics still inject), international and Type-2 optionality, at only an ~$11B cap — genuine room to run. Docked from higher because the launch-driven acceleration has passed; growth now gently decelerates (23% → 19% → 18% FY26→28E). |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. We anchor on FY27E EPS (the first "clean" post-de-rating year with 19 revenue / 14 EPS analysts).
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | International + Type-2 accelerate; pharmacy switchers stay strong; margin expansion beats. FY27E EPS beats to ~$9.0 (vs $8.11 cons); the market re-rates a re-accelerating grower back to ~28×. | ~$252 (+53%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS $8.11; a ~20% grower with 71% GM and clean leverage earns a ~24× forward multiple. | ~$195 (+19%) |
| Bear | A CGM-partner disruption, a tubeless competitor, GLP-1-driven pump-demand fear, or a growth stall. FY27E EPS misses to ~$7.0; multiple de-rates to ~16× (a broken growth story). | ~$112 (−32%) |
Synthos fair value = the base case, ~$195 (+19%), with the full $112–$252 span as the honest range. Our base sits below the Street's $221 consensus — we apply a more conservative forward multiple to a single-product name in a downtrend — while our bull roughly meets the Street's high. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). PODD sits between the two — a high-quality grower with real runway but past its steepest acceleration:
- Forward growth: revenue CAGR FY25→FY30E ~17.6% ($2.71B → $6.10B est); GAAP-EPS CAGR ~33% ($3.51 → $14.49 est) as operating leverage compounds. On the cleaner near-term window, revenue CAGR FY25→FY27E is ~20.8%.
- Acceleration (the 2nd derivative) is mildly negative: revenue growth +30.7% (FY25) → +23.0% (FY26E) → +18.7% (FY27E) → +18.4% (FY28E) → +16.9% (FY29E). The Omnipod 5 launch inflection has largely played out; from here PODD decelerates toward a high-teens compounder. Note Q1'26 still printed +33.9% reported — the deceleration is a forward-estimate story, not yet in the price.
- Room to run: the binding constraint is not market cap — at ~$11B, a 3× is a ~$34B company, entirely plausible for a device leader; it's category penetration. Most insulin-dependent diabetics worldwide still use MDI, and the Type-2 / fully-closed-loop opportunity (EVOLVE study, 510(k) targeted 2027) opens a materially larger TAM. Demand runway is real.
- Reinvestment runway: productive capex (~$192M FY25, capacity for pod manufacturing) with FCF firmly positive ($377.7M FY25) — self-funding growth, not a cash-burn story.
Exponential Potential: Moderate-High (6/10). Own it for durable high-teens-to-20% compounding plus genuine penetration and Type-2 optionality, not for a fast multibagger — the acceleration phase is behind it. The small cap and open TAM are what keep this above a mega-cap compounder's score.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $2,708.1M, +30.7% (FY24 $2,071.6M, +22.1% on FY23 $1,697.1M). Multi-year 20-30% top-line at scale.
- Quarterly trajectory: Q1'25 $569.0M → Q2 $649.1M → Q3 $706.3M → Q4 $783.8M → Q1'26 $761.7M (+33.9% YoY). Note the normal Q4→Q1 seasonal dip; the YoY comparison is what matters and it re-accelerated.
- Margins: gross 71.0% TTM, EBITDA margin ~19.8%, operating ~17.5% and rising (management guides +100bps adj-operating-margin expansion FY26). Net margin 10.4% TTM.
- Earnings: GAAP net income $247.1M FY25 (EPS $3.51 / dil $3.48). Note the FY24 GAAP figure ($418.3M, EPS $5.97) was inflated by a ~$137M one-time deferred-tax benefit in Q2'24 — FY25 GAAP EPS is down YoY for that tax-comparison reason, not operational weakness. On an adjusted basis Q1'26 adj-EPS was $1.42, +39.7%, and management guides ~25% full-year adj-EPS growth — the cleaner read on earnings power.
- Cash flow: operating CF $569.3M, capex −$191.6M, FCF $377.7M FY25 (FCF yield ~3.4%) — a strong inflection from $70M (FY23) and negative (FY22) as the business scaled past its investment hump.
- Balance sheet: cash $716M, total debt $1.05B, net debt $335M, net-debt/EBITDA 0.81× — investment-grade and easily serviceable. The company also repurchased ~1.25M shares in Q1'26 and ~$60M for FY25 — a first for a former cash-burner.
6. Valuation — priced in or room?
PODD is not statistically cheap on trailing numbers (38× GAAP EPS, 8.8× book, 4.1× EV/sales, 20.6× EV/EBITDA) — but the ~53% drawdown has done real work. The bull's case is that earnings grow into the multiple fast: on live consensus the forward P/E is 25× (FY26E) → 20× (FY27E) → 16× (FY28E) → 11× (FY30E). A ~20% grower at ~20× next-year earnings is a reasonable, not stretched, price — the PEG-style read (FMP forward PEG ~1.5) is fair for the quality. The EV/EBITDA of 20.6× against ~20% EBITDA growth is similarly defensible.
The honest caveat: 4.1× EV/sales and 38× trailing still price in continued execution, and a single-product name in a downtrend deserves a discount to a diversified compounder — which is why our base multiple (24× FY27E) sits below where the Street implicitly anchors. Street targets (context): consensus $221, high $280, low $190 — even the Street low is above today's $164, i.e. the analyst community views the drawdown as an overshoot. Our $195 base is more conservative than consensus. Not a deep-value buy; a quality-grower-on-sale buy with a margin of safety created by the crash.
7. Technicals (from the tech block)
- Trend: down, basing. $164.48 sits above the 50-DMA ($156.7) but far below the 200-DMA ($247.8) — a death-cross posture. The 200-DMA is a long way overhead, confirming the primary trend is still down.
- Location: −53% off the 52-week high ($354.88), only +18% off the 52-week low ($138.79). Max drawdown from peak −53.4% — this is a genuinely broken chart, not a healthy pullback.
- Momentum: RSI(14) 64 — firm and approaching-but-not-overbought after a bounce off the lows; MACD marginally positive (+0.40). The near-term tape has stabilized above the 50-DMA.
- Relative strength (the tell): PODD −45.2% 12-mo vs SPY +20.6% and QQQ +30.3%; −20.6% 3-mo vs SPY +13.7%. Persistent, severe underperformance of both market and Nasdaq — the market has been selling this name, not accumulating it.
- Read: technicals do not confirm the fundamental thesis — they warn. The stock is basing above its 50-DMA but under a falling 200-DMA. This argues strongly for scaling in rather than a lump-sum entry, and for treating a reclaim of the 200-DMA (~$248) as the trend-change signal. The gap between crashing price and still-growing fundamentals is exactly the tactical setup — and its risk.
8. Moat & competitive position
Insulet's moat is narrower than a diversified pharma's but real within its niche: (1) the only pod-form tubeless AID at scale — a genuine form-factor differentiator patients prefer; (2) pharmacy-channel distribution — dispensed as a pharmacy benefit rather than durable medical equipment, which lowers the switching barrier for MDI patients and is hard for tubed-pump incumbents to replicate; (3) an installed base of recurring, disposable-pod revenue — razor-and-blade economics with high reorder rates; (4) CGM interoperability (Dexcom and Abbott Libre), reducing single-partner dependence. The competitive frame is a pump oligopoly with Tandem (t:slim/Mobi) and Medtronic (MiniMed), plus the structural swing factor of GLP-1 drugs potentially altering the Type-2 and even Type-1 treatment mix.
Peer set (FMP-supplied med-device / diagnostics comps, market cap): DexCom $27.5B (the closest diabetes-tech comp and a CGM partner), Zimmer Biomet $16.9B, West Pharma $25.8B, Waters $24.7B, STERIS $21.3B, Labcorp $23.5B, Quest $23.9B, Biogen $31.9B, Philips $26.9B, Smith & Nephew $12.8B. Note: this FMP peer list is a broad healthcare-device basket, not a pure-play pump set — Insulet's truest comps (Tandem, Medtronic Diabetes) aren't in it. PODD carries the highest revenue growth in the group, which is what justifies its premium multiple — and what a stall would remove.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and maturing — ~$192M/yr capex into pod-manufacturing capacity, FCF now firmly positive ($378M), and the company began repurchasing shares (~1.25M in Q1'26; ~$60M FY25) while paying down net debt (net-debt/EBITDA fell 0.81×). No dividend. This is a growth-reinvestment posture, appropriate at 16% ROIC.
- Insider activity: mixed but not alarming — mostly routine director stock awards; notably a director open-market purchase (Stonesifer, 2,790 sh @ $143.51 on 2026-06-03) near the lows, a modest positive signal, against one small director sale (418 sh). No cluster of alarming discretionary selling in the sampled window.
- Management's own guidance (the earnings-call track — half-weighted, self-interested): Guidance was available and reads like a real earnings release. From the Q1'26 8-K (2026-05-06, "Insulet Reports First Quarter 2026 Results — Raises Full Year Total Company Revenue Guidance"): management raised the FY26 outlook to Total revenue +21% to +23% constant-currency (from +20-22%), Total Omnipod +22% to +24%, driven by International Omnipod +26-28%; plus ~100 bps adjusted-operating-margin expansion and ~25% adjusted-EPS growth for FY26. Q2'26 guide: Total +20-22% CC. CEO Ashley McEvoy: "We started the year strong… raising our total company revenue growth outlook to reflect our progress." Treat as management's own self-interested framing (half-weight) — but the raise and the constant-currency beat (+30.1% vs a 25-27% guide) in Q1 are corroborated by the reported numbers.
10. Catalysts & what to watch
- Next earnings: 2026-08-05 (Q2'26; Street EPS $1.45, revenue ~$788M). Key lines: International Omnipod growth (the swing factor), U.S. new-patient starts / MDI switchers, and adjusted operating margin vs the +100bps guide.
- Omnipod 5 international expansion: now in 19 countries after five Middle East launches; broadening algorithm updates and CGM connectivity (FreeStyle Libre 3 Plus limited release).
- Type-2 / fully-closed-loop: EVOLUTION 2 data at ATTD and the EVOLVE pivotal study (first patient enrolled) supporting a 510(k) filing targeted 2027 — the biggest TAM-expansion catalyst.
- Competitive / structural: Tandem and Medtronic pump moves; and the GLP-1 question — whether weight-loss/Type-2 drugs expand or erode the addressable pump population.
- Chart: a reclaim of the 200-DMA (~$248) would confirm a trend change; failure to hold the 50-DMA (~$157) would reopen the lows.
Thesis tripwires (what would change the call): a quarter of Omnipod volume deceleration below mid-teens; guidance cut; adjusted-operating-margin contraction; a CGM-partner disruption; or credible evidence GLP-1 adoption is shrinking the pump TAM.
11. Key risks
- Single-product concentration (structural): Omnipod is ~99% of revenue. A competitive, clinical, reimbursement, or supply shock hits the entire company at once — the dominant risk and the reason for Tactical (not Core) sizing.
- Valuation / de-rating: 38× trailing and 4.1× EV/sales leave room for further multiple compression if growth disappoints — the ~53% drawdown shows how violently this name re-rates.
- Broken technical trend: price is deep below a falling 200-DMA and has trailed the market by ~65 points over 12 months; the market is pricing a problem we should respect.
- GLP-1 disruption: weight-loss/Type-2 drugs could reshape diabetes treatment in ways that reduce (or grow) the insulin-pump population — a genuine unknown.
- CGM-partner dependence: Omnipod 5 automation requires third-party CGMs (Dexcom, Abbott); a partnership or interoperability disruption would impair the flagship product.
- No expert corroboration: unlike our conviction names, no independent Synthos-panel voice supports this thesis — the evidence base is narrower by construction.
12. Verdict, position sizing & monitoring
Buy — Tactical. Insulet is a high-quality, ~20% grower (FY25 revenue +30.7%, 71% gross margin, ROIC 16%, FCF $378M, clean 0.8× leverage) whose stock has been cut in half — creating a rare gap between a still-accelerating business and a broken chart. At ~20× FY27E earnings the price is reasonable for the growth, and management just raised guidance. But the verdict is Tactical, not Core, for three honest reasons: (1) ~99% single-product concentration, (2) a still-downtrending technical picture below a falling 200-DMA, and (3) zero expert coverage in the Synthos KB — the call rests on fundamentals and quant alone.
- Sizing: satellite growth, ~2–3% of the book — and scale in (a starter now, adds on a 200-DMA reclaim or a further flush toward the 52-week low), never a lump sum into a falling knife.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $164.48.
- Single biggest risk: single-product concentration — the whole thesis depends on the Omnipod franchise staying dominant.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage for PODD in the Synthos knowledge base, and no
claim_idis cited (none exist). The verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation); here we simply have none to reconcile, and say so. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Management caveat: the FY26 guidance in §9 is management's own book (SEC 8-K, 2026-05-06), half-weighted by design; corroborated by the reported Q1'26 beat.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").